---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-028373"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:48:33.567219+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Incannex completes Phase 2 enrollment in RePOSA trial of IHL-42X for OSA; topline data expected H1 2025

## Summary
- Completed enrollment of >120 patients across 11 U.S. sites in Phase 2 dose-finding portion of RePOSA Phase 2/3 study of IHL-42X for OSA.
- Topline Phase 2 clinical data expected in first half 2025; results will determine optimal dose for Phase 3.
- Phase 3 expansion planned with ~440 patients across four treatment arms over 52 weeks to support future FDA NDA submission.
- IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide targeting physiological pathways of OSA.

## SEC filing metadata
- accession: 0001213900-25-028373
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/0001213900-25-028373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/ea0237061-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-028373
- JSON: https://secwatch.observer/filing/0001213900-25-028373.json
- Plain text: https://secwatch.observer/filing/0001213900-25-028373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.